Cady, Roger, M.D.

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Cady, Roger, M.D. sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 9 completed later-stage tilt top decile by trial count

Cady, Roger, M.D.: 12 sponsored US clinical trials, none currently recruiting.

Cady, Roger, M.D. sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 9 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Menstrual Migraine, with 1 trials.

Top-decile sponsor footprint

Cady, Roger, M.D. ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

TERMINATED Phase 2

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

NCT02381795
COMPLETED Phase 2

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
COMPLETED Phase 2

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
COMPLETED Phase 4

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
COMPLETED Phase 4

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
COMPLETED Phase 4

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
COMPLETED Phase 4

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
COMPLETED Phase 4

Treximet in the Treatment of Chronic Migraine

NCT01090050
COMPLETED Phase 4

Calcitonin Gene-related Peptide Levels in Chronic Migraine

NCT01071096
TERMINATED Phase 4

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT01053507
COMPLETED Phase 4

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737
TERMINATED Phase 4

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT00487578

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 4 9

Therapeutic Areas

Menstrual Migraine 1
Chronic Migraine 1

How the Cady, Roger, M.D. archive is shaped

12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).

Phase mix: 9 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Menstrual Migraine (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cady, Roger, M.D.: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Cady, Roger, M.D.Alachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cady, Roger, M.D. page

12 registered trials is a research-attention snapshot, not an endorsement of Cady, Roger, M.D. or any single study.

  • None of Cady, Roger, M.D.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Menstrual Migraine is the condition Cady, Roger, M.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Menstrual Migraine trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cady, Roger, M.D. pipeline card: 12 registered trials from official public datasets.Report a data error.